Discussion about this post

User's avatar
Dr. Molly Rutherford's avatar

Unfortunately, as with opioids, we overcorrected on this issue. Absolute risk is something we need to consider as physicians. Let’s return to treating the individual, considering that person's values, risks, and potential benefits of a treatment. Maybe then, after the past embarrassing 2 years for our profession, we can regain the public’s trust.

Expand full comment
Just_Henry's avatar

A couple items. First, all “studies” begin with a single observation. It’s the genesis, the seed, for an hypothesis then a testable theory. So observational studies are powerful in that they guide innovation. A serious problem with studies looking for statistical power is the systematic introduction of error that can dilute or eliminate real effects that are actually real as observed in the case study. This happens often when the suspected treatment agent is only effective when interacting with a second unidentified factor, or there is an unidentified factor responsible for the observation. Jumping to a parametric study will only find no effect and the discovery is lost. Second, in the HRT study the assumption that E reducing LDLs as the mechanism reducing cardiovascular events is errant leading to the finding of no effect in the parametric study. Many studies have shown that cholesterol is not the relevant factor in CVD, the relevant factor is vascular inflammation. In fact, the relevant variable in the study mentioned is actually vitamin D status and its effects on reducing inflammation hence CVD. So, while E is a minor agonist of vitD, the heavy lifting with respect to CVD was vitD. So here we have that second unidentified, unappreciated, ignored? variable that is responsible for the observed effect. Don’t get me started on why vitD, a free, safe, readily available agent is systematically villified/ignored by the medical community. I think it has something to do with $$$.

Expand full comment
98 more comments...

No posts